| Name | Title | Contact Details |
|---|
Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.
Compass Therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. Novel scientific insights are validated and explored deeply inside our labs before Compass pursues the best proprietary combinations of therapeutics into human clinical trials.
Greiner Bio One Inc is a Monroe, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.